<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Han B</submitter><funding>Ministry of Education, Science and Technology</funding><funding>National Research Foundation of Korea</funding><pagination>92-96</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8934995</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>56(2)</volume><pubmed_abstract>Microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status has been approved as a tissue-agnostic biomarker for immune checkpoint inhibitor therapy in patients with solid tumors. We report the case of an MSI-H/dMMR diffuse large B-cell lymphoma (DLBCL) identified by targeted gene sequencing (TGS). A 90-year-old female who presented with vaginal bleeding and a large mass in the upper vagina was diagnosed with germinal center-B-cell-like DLBCL, which recurred at the uterine cervix at 9 months after chemotherapy. Based on TGS of 121 lymphoma-related genes and the LymphGen algorithm, the tumor was classified genetically as DLBCL of EZB subtype. Mutations in multiple genes, including frequent frameshift mutations, were detected by TGS and further suggested MSI. The MSI-H/dMMR</pubmed_abstract><journal>Journal of pathology and translational medicine</journal><pubmed_title>An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing.</pubmed_title><pmcid>PMC8934995</pmcid><funding_grant_id>2016R1D1A1B01015964</funding_grant_id><pubmed_authors>Kim S</pubmed_authors><pubmed_authors>Han B</pubmed_authors><pubmed_authors>Yun H</pubmed_authors><pubmed_authors>Bae JM</pubmed_authors><pubmed_authors>Koh J</pubmed_authors><pubmed_authors>Jeon YK</pubmed_authors></additional><is_claimable>false</is_claimable><name>An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing.</name><description>Microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status has been approved as a tissue-agnostic biomarker for immune checkpoint inhibitor therapy in patients with solid tumors. We report the case of an MSI-H/dMMR diffuse large B-cell lymphoma (DLBCL) identified by targeted gene sequencing (TGS). A 90-year-old female who presented with vaginal bleeding and a large mass in the upper vagina was diagnosed with germinal center-B-cell-like DLBCL, which recurred at the uterine cervix at 9 months after chemotherapy. Based on TGS of 121 lymphoma-related genes and the LymphGen algorithm, the tumor was classified genetically as DLBCL of EZB subtype. Mutations in multiple genes, including frequent frameshift mutations, were detected by TGS and further suggested MSI. The MSI-H/dMMR</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T23:03:58.245Z</modification><creation>2025-04-04T23:03:58.245Z</creation></dates><accession>S-EPMC8934995</accession><cross_references><pubmed>34775735</pubmed><doi>10.4132/jptm.2021.10.15</doi></cross_references></HashMap>